Risedronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women
about
Interventions for treating bisphosphonate-related osteonecrosis of the jaw (BRONJ)Bisphosphonates for preventing and treating osteoporosis in menBisphosphonates for osteoporosis in people with cystic fibrosisChinese herbal medicines for treating osteoporosisSelective estrogen receptor modulators for preventing and treating postmenopausal osteoporosisExercise for improving outcomes after osteoporotic vertebral fractureDenosumab for the treatment and prevention of postmenopausal osteoporosisHuman parathyroid hormone for the treatment of osteoporosis in post-menopausal womenBisphosphonates for osteoarthritisPharmacologic interventions for preventing and treating periprosthetic osteoporosis following total hip arthroplastyBisphosphonates for osteoporosis in primary biliary cirrhosisHormone replacement for osteoporosis in women with primary biliary cirrhosisIntravenous zoledronate for postmenopausal osteoporosisWhole body vibration for preventing and treating osteoporosisVitamin K for the prevention and treatment of osteoporosis in post-menopausal womenOnce-yearly zoledronic acid in hip fracture preventionSurgical prevention of femoral neck fractures in elderly osteoporotic patients. A literature reviewMechanism and Treatment Strategy of Osteoporosis after TransplantationInflammatory eye reactions with bisphosphonates and other osteoporosis medications: what are the risks?The effects of a novel hormonal breast cancer therapy, endoxifen, on the mouse skeletonMind the (treatment) gap: a global perspective on current and future strategies for prevention of fragility fractures.Cancer treatment-related bone disease.Treating osteoporosis in Canada: what clinical efficacy data should be considered by policy decision makers?Bisphosphonates and atrial fibrillation: Bayesian meta-analyses of randomized controlled trials and observational studies.The correlation of osteoporosis to clinical features: a study of 4382 female cases of a hospital cohort with musculoskeletal symptoms in southwest ChinaFracture Preventing Effects of Maxmarvil® Tablets (Alendronate 5 mg + Calcitriol 0.5 µg) in Patients with OsteoporosisIs bisphosphonate therapy for benign bone disease associated with impaired dental healing? A case-controlled studyApplication of the National Osteoporosis Foundation Guidelines to postmenopausal women and men: the Framingham Osteoporosis StudyLow acceptance of treatment in the elderly for the secondary prevention of osteoporotic fracture in the acute rehabilitation settingOral bisphosphonates and risk of cancer of oesophagus, stomach, and colorectum: case-control analysis within a UK primary care cohort.New strategies for osteoporosis patients previously managed with strontium ranelate.Efficacy and safety of risedronate 150 mg once a month in the treatment of postmenopausal osteoporosisComparing tolerability and efficacy of generic versus brand alendronate: a randomized clinical study in postmenopausal women with a recent fracture.Risedronate does not reduce mechanical loading-related increases in cortical and trabecular bone mass in miceIncorporating bazedoxifene into the treatment paradigm for postmenopausal osteoporosis in Japan.Risk of atypical femoral fracture during and after bisphosphonate use.Use of oral bisphosphonates in primary prevention of fractures in postmenopausal women: a population-based cohort study.Baseline age and time to major fracture in younger postmenopausal women.Bisphosphonates: forever or 5 years and stop?Risedronate's Role in Reducing Hip Fracture in Postmenopausal Women with Established Osteoporosis.
P2860
Q24186105-7BF3C917-61CC-4EAB-98B2-8F6622BFE75BQ24197612-89239AE9-550E-4D84-BC7A-4B882785D002Q24197936-AC598B29-2BCA-4DBD-B274-55C7A4721BB8Q24198040-59FD2B5B-3DB3-4500-83CC-7EE2DC2D2F54Q24200755-3B1655C2-646D-4691-9CD6-729B6F78A750Q24201831-123C6FE3-A40D-4B20-B123-73E478537B00Q24201859-A5F153F8-0950-4722-9AD9-D494D7E7A4CBQ24202763-BA6B63EF-3AB5-4343-B8F7-F69F0B62FF1AQ24202794-C8D0FA94-928E-4F69-9ED3-1EAE584A952DQ24202797-38536C10-1170-493A-82E8-C59E315CABAEQ24234283-3F9D51C0-03FA-4D92-BBEF-E52769B9ECFEQ24234575-145851E1-B559-49B6-B55B-0ED8A7BE2AE1Q24239823-F9DEBA02-EDDB-455C-AAB9-8625BF5F7016Q24239866-FAD62578-E965-41E3-97C0-6B37775AFF77Q24239937-B1E0D9AA-A4DF-4970-9A54-0BAC52711DE2Q24657667-2852C22D-8066-45E0-89EB-297375F4A239Q26744057-84D5523D-8C51-4541-9055-10C2C5DC8E8CQ26798296-E666B4A6-B76C-477D-B1F4-A712E3AC7262Q27024738-56C36FB6-ED4C-4220-A260-A0C496AA8B07Q28539057-2F9A594B-5359-4AD4-804B-F2711C396E3FQ30236007-F8D545EA-A8BE-43C9-BB25-7A62E9EAD170Q30438185-27AF6CC4-1E91-4363-A932-37D00530CD14Q33416959-C1E72315-3791-4DF7-ABB1-E1395B0E02B2Q33505798-7CA5D021-3250-4141-85C5-4BA388734DFFQ33659574-3CCA1B5C-AB7B-43DD-9BF7-2288CB563742Q33804860-F1B019F2-628D-4861-BF2B-D1EC4E746833Q33866456-9DB669E7-1C6E-4448-8ED0-3491BC6174A0Q33929951-5A26E1C0-AA63-49E1-8935-F440A7E6A8D0Q34055595-1C018F25-BC84-417F-B113-31DEBCD5E12FQ34104102-AA53B7AB-6937-497D-832E-E5C5BD15FB47Q34550435-56118C64-CC90-4211-8652-1AEF4DD14E5CQ34658660-E2F1FD87-3507-47B8-A6A8-0B9804536FD8Q35036120-589C8B2C-4DE0-46E7-AD00-39D325B66E8DQ35059092-6E65C9DC-B928-41AB-B16C-E437B9C063EAQ35092609-791F59BB-4470-46B2-A665-7E0976D28CC7Q35197628-4E449F67-3EF3-4B99-B7E4-A9C6EDC5E0C5Q35364745-9B301CCC-7118-4396-BEEE-6EDE9B53F31FQ35542877-3D219D81-65D3-4F06-9836-B6243334937BQ35601553-740C07D0-2792-4D38-9D74-80FA64299C79Q35678676-EBABD890-9EFC-4E3F-8089-9BBF10D96375
P2860
Risedronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women
description
2008 nî lūn-bûn
@nan
2008 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
name
Risedronate for the primary an ...... ctures in postmenopausal women
@ast
Risedronate for the primary an ...... ctures in postmenopausal women
@en
Risedronate for the primary an ...... ctures in postmenopausal women
@en-gb
Risedronate for the primary an ...... ctures in postmenopausal women
@nl
type
label
Risedronate for the primary an ...... ctures in postmenopausal women
@ast
Risedronate for the primary an ...... ctures in postmenopausal women
@en
Risedronate for the primary an ...... ctures in postmenopausal women
@en-gb
Risedronate for the primary an ...... ctures in postmenopausal women
@nl
prefLabel
Risedronate for the primary an ...... ctures in postmenopausal women
@ast
Risedronate for the primary an ...... ctures in postmenopausal women
@en
Risedronate for the primary an ...... ctures in postmenopausal women
@en-gb
Risedronate for the primary an ...... ctures in postmenopausal women
@nl
P2093
P2860
P1476
Risedronate for the primary an ...... ctures in postmenopausal women
@en
P2093
Ann Cranney
Doug Coyle
George A Wells
Joan Peterson
Michel Boucher
Vivian Welch
P2860
P356
10.1002/14651858.CD004523.PUB3
P577
2008-01-23T00:00:00Z